10:15 AM - 10:30 AM (JST), Wednesday, March 6, 2019 ・ 2nd Floor
InveniAI has pioneered the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across biopharma and adjacencies. Our sister company, BioXcel Therapeutics, is the first AI powered drug company listed on NASDAQ (March, 2018).

Our platform – AlphaMeldTM, monitors millions of data points in real time with industry-aware scoring algorithms that are customized by incorporating continuous feedback through machine learning.

AlphaMeld Platform Capabilities Include:

First Mover Advantage to Access Emerging Innovation - Fully automated AI/ML based signal detection platform.
• Access, monitor, predict breakthrough events – targets, drugs, technologies, and therapeutic areas with break-out diseases

Drug Discovery Analytics - Machine based clinical hypothesis generation for decoding hidden connections between targets and MoAs with diseases.
• Generate clinical hypotheses, Optimize therapeutic value of drugs, modalities and platforms
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Multiple Therapeutics
Lead Product in Development:
AlphaMeld Platform
Development Phase of Primary Product:
Other/Not Applicable
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided